From looking at the program, there were only 2 accepted oral papers for the Cancer of the Pancreas session - the rest are invited or panel discussions.
So,that's excellent.
Also I note a panel discussion on borderline resectable/non-resectable definitions, which would go a long way toward addressing the appropriate patient groups for oncosil treatment in future studies.
Ann: OncoSil PanCO Clinical Trial Presented At ESMO World WCGIC, page-5
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.07 |
Change
-0.010(0.93%) |
Mkt cap ! $20.14M | |||
| Open | High | Low | Value | Volume |
| $1.08 | $1.08 | $1.06 | $16.77K | 15.64K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 6725 | $1.07 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.08 | 11531 | 2 |
View Market Depth
| Last trade - 16.10pm 31/07/2025 (20 minute delay) ? |
| OSL (ASX) Chart |